Abstract 1091: MDM2 inhibition as a novel radio-sensitizing strategy for endometrial cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1091
Abstract: Introduction: As opposed to other malignancies, the majority of endometrial cancer (EC) cases are wild-type for TP53. Approximately 15% of TP53-mutated EC have heterozygous mutation, preserving a fraction of wild-type signaling. Given the demonstrated impact… read more here.
Keywords: cell; radio sensitizing; mdm2 inhibition; tp53 ... See more keywords
Targeting MDM2 enhances anti-leukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2022016082
Abstract: Patients with acute myeloid leukemia (AML) often achieve remission after allogeneic hematopoietic cell transplantation (allo-HCT), but subsequently die of relapse that is driven by leukemia cells resistant to elimination by allogeneic T-cells based on decreased… read more here.
Keywords: trail; mhc; aml; leukemia ... See more keywords
Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24032410
Abstract: Several molecular subtypes of cancer are highly dependent on splicing for cell survival. There is a general interest in the therapeutic targeting of splicing by small molecules. E7107, a first-in-class spliceosome inhibitor, showed strong growth… read more here.
Keywords: mdm2 inhibition; splicing modulation; mdm2; modulation results ... See more keywords